Immunocellular Therapy Treatment Process
Current Status of Cellular Therapy in Taiwan
Taiwan is the second country in the world to legalize autologous immune cell therapy.
In September 2018, Taiwan's Ministry of Health and Welfare issued the "Administrative Regulation on Special Medical Instruments and Inspection Techniques".
Currently, the regulation allows the use of the following autologous immune cell therapies for cancer:
- Cytokine Induced Killer Cells (CIK)
- NK、DC、DC-CIK、Tumor In- filtrative Lymphocytes (TIL)
- Gamma-delta T cell adoptive therapy
Approved Applications of Cellular Therapy under the Administrative Regulation:
The therapy is limited to patients in the following three situations:
-
Hematological malignancies that are unresponsive to standard treatments.
-
Stage 1-3 solid tumors that are unresponsive to standard treatments.
-
Patients with stage 4 solid tumors, due to legal regulations, can primarily receive autologous immune cell therapy, meaning the cells used must originate from the patient's own body.
3 Steps of Immunocellular Cancer Therapy
Lukas Biomedical’s immunocellular therapy using "Memory T Cells" involves a simple procedure that requires only a single blood draw to complete the entire treatment. This approach lets patients maintain a good quality of life and serves as a beneficial treatment option for cancer patients.
The treatment process for anti-cancer immunocellular therapy is as follows:
Step 1: Cellular Consultation and Evaluation
Medical institutions partnered with Lukas Biomedical will have a physician evaluate the patient → perform blood tests and draw blood (only a single draw of about 100ml is needed for culture)
Step 2: Lukas Cellular Laboratory
Specialists will send the cultured blood to the GTP laboratory → isolate immune cells from the blood, and use proprietary expansion and culture technology (after approximately 2-3 weeks, the number of memory T cells can be expanded to nearly 10 billion).
Step 3: Reinfusion Treatment at the Hospital
The hospital will notify the patient to return for cell reinfusion. This process has minimal side effects and maintains a good quality of life for cancer patients (a total of six doses, with one dose administered every 1-2 weeks).